Diagnosis of Platelet Function Disorders: A Challenge for Laboratories.
暂无分享,去创建一个
[1] C. Klersy,et al. Preoperative bleeding risk assessment with ISTH‐BAT and laboratory tests in patients undergoing elective surgery: A prospective cohort study , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.
[2] W. Willinek,et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia , 2021, Haematologica.
[3] M. Gawaz,et al. Antibody-induced procoagulant platelets in severe COVID-19 infection , 2020, Blood.
[4] C. Balduini,et al. Inherited thrombocytopenias: an updated guide for clinicians. , 2020, Blood reviews.
[5] T. Bakchoul,et al. Flow Cytometric Assessment of AKT Signaling in Platelet Activation: An Alternative Diagnostic Tool for Small Volumes of Blood , 2020, Hämostaseologie.
[6] L. Alberio,et al. Flow Cytometric Monitoring of Dynamic Cytosolic Calcium, Sodium, and Potassium Fluxes Following Platelet Activation , 2020, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[7] M. Harper,et al. Supramaximal calcium signaling triggers procoagulant platelet formation. , 2020, Blood advances.
[8] M. Ranucci,et al. Sensitivity of Viscoelastic Tests to Platelet Function , 2020, Journal of clinical medicine.
[9] Sri V. V. Deevi,et al. Next‐generation sequencing for the diagnosis of MYH9‐RD: Predicting pathogenic variants , 2019, Human mutation.
[10] P. Noris,et al. Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report , 2019, HemaSphere.
[11] S. Kunishima,et al. Renin-angiotensin System Blockade Therapy for Early Renal Involvement in MYH9-related Disease with an E1841K Mutation , 2019, Internal medicine.
[12] K. Jurk,et al. Standardization of Light Transmission Aggregometry for Diagnosis of Platelet Disorders: An Inter-Laboratory External Quality Assessment , 2019, Thrombosis and Haemostasis.
[13] T. Bakchoul,et al. Diagnose der Thrombozytenfunktionsstörungen – eine Herausforderung im Labor , 2019, Transfusionsmedizin - Immunhämatologie, Hämotherapie, Immungenetik, Zelltherapie.
[14] H. ten Cate,et al. Screening for platelet function disorders with Multiplate and platelet function analyzer , 2019, Platelets.
[15] H. Schulze,et al. Functional Classification of Paediatric Patients with Non-syndromic Delta-Storage Pool Deficiency , 2018, Hämostaseologie.
[16] H. ten Cate,et al. Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice , 2018, Research and practice in thrombosis and haemostasis.
[17] P. Nurden,et al. Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders , 2017, Journal of thrombosis and haemostasis : JTH.
[18] P. Nurden,et al. Bleeding risk of surgery and its prevention in patients with inherited platelet disorders , 2017, Haematologica.
[19] C. Porter. Germ line mutations associated with leukemias. , 2016, Hematology. American Society of Hematology. Education Program.
[20] Ernest Turro,et al. Inherited platelet disorders: toward DNA-based diagnosis. , 2016, Blood.
[21] L. Ardillon,et al. Platelet function analyser (PFA‐100) results and von Willebrand factor deficiency: a 16‐year ‘real‐world’ experience , 2015, Haemophilia.
[22] P. Gresele. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[23] C. Gachet,et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey , 2014, Journal of thrombosis and haemostasis : JTH.
[24] A. Schmaier,et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH , 2013, Journal of thrombosis and haemostasis : JTH.
[25] E. Vicaut,et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.
[26] R. Scharf. Drugs that Affect Platelet Function , 2012, Seminars in Thrombosis & Hemostasis.
[27] G. Stone,et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.
[28] B. Konkle. Acquired disorders of platelet function. , 2011, Hematology. American Society of Hematology. Education Program.
[29] N. Schork,et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.
[30] J. Zehnder,et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. , 2010, American journal of clinical pathology.
[31] B. Coller,et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders , 2010, Journal of thrombosis and haemostasis : JTH.
[32] A. Michelson,et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH , 2009, Journal of thrombosis and haemostasis : JTH.
[33] M. Cattaneo. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. , 2009, Seminars in thrombosis and hemostasis.
[34] A. Greinacher,et al. MYH9-related platelet disorders. , 2009, Seminars in thrombosis and hemostasis.
[35] P. Noris,et al. Position of nonmuscle myosin heavy chain IIA (NMMHC‐IIA) mutations predicts the natural history of MYH9‐related disease , 2008, Human mutation.
[36] F. Lussana,et al. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. , 2007, Haematologica.
[37] W. Siess,et al. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood , 2006, Thrombosis and Haemostasis.
[38] S. Ziemer,et al. A Practical Concept for Preoperative Identification of Patients with Impaired Primary Hemostasis , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[39] D. Mikhailidis,et al. Value of Thromboelastography in the Assessment of Platelet Function , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[40] J. Brandt,et al. The Preoperative Bleeding Time Test Lacks Clinical Benefit. College of American Pathologists' and American Society of Clinical Pathologists' Position Article , 1998 .
[41] Reinhold Förster,et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.
[42] C. Arkin,et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. , 1998, Archives of surgery.
[43] S. Israels,et al. The Lysosomal Granule Membrane Protein, Lamp-2, Is also Present in Platelet Dense Granule Membranes , 1996, Thrombosis and Haemostasis.
[44] A. Gewirtz,et al. The preoperative bleeding time test: assessing its clinical usefulness. , 1995, Cleveland Clinic journal of medicine.
[45] J. Arnold,et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents , 1995, British journal of haematology.
[46] M. Nishibori,et al. The protein CD63 is in platelet dense granules, is deficient in a patient with Hermansky-Pudlak syndrome, and appears identical to granulophysin. , 1993, The Journal of clinical investigation.
[47] N. Rote,et al. Production of monoclonal antibodies specific for platelet activation antigens and their use in evaluating platelet function. , 1990, Hybridoma.
[48] R. Silverstein,et al. Identification and characterization of LAMP-1 as an activation-dependent platelet surface glycoprotein. , 1990, Journal of Biological Chemistry.
[49] M. Ginsberg,et al. Mechanisms for Expression of Thrombospondin on the Platelet Cell Surface , 1987, Seminars in thrombosis and hemostasis.
[50] C. Mielke,et al. The standardized normal Ivy bleeding time and its prolongation by aspirin. , 1969, Blood.
[51] G. Born,et al. Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.
[52] P. Kolh,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[53] B. Olas. Dietary Supplements with Antiplatelet Activity: A Solution for Everyone? , 2018, Advances in nutrition.
[54] M. Franchini. The platelet function analyzer (PFA-100): an update on its clinical use. , 2005, Clinical laboratory.
[55] U. Walter,et al. Platelet-vessel wall interactions, focal adhesions, and the mechanism of action of endothelial factors. , 1995, Agents and actions. Supplements.
[56] J. V. van Oosterhout,et al. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. , 1987, Blood.